Circumvention of human tumor drug resistance

Details Circumvention of human tumor drug resistance Circumvention of human tumor drug resistance

1995-02-28

1996-12-17

Rollins, John W.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514 46, 514 49, 514 50, 514210, 424450, A61K 3170, A61K 31395, A61K 9127

Patent

active

055853633

ABSTRACT:
A method involving the administration of nucleoside analogs to circumvent resistance attributable to the enhanced DNA repair capacity of cancer cells is described. The nucleoside analogs function as suicide substrates for DNA repair enzymes. A method of screening nucleoside analogs for utility as antitumor agents and a screening assay to individual recurrent tumors is described.

REFERENCES:
patent: 5049389 (1991-09-01), Radhakrishnan
patent: 5166140 (1992-10-01), Scanlon et al.
J. A. Double et al Anti-Cancer Drugs Design. 1:133-139, 1986.

Affiliated with

Also associated with

Rating

Circumvention of human tumor drug resistance does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Circumvention of human tumor drug resistance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Circumvention of human tumor drug resistance will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1991420